The International Classification of Diseases (ICD) is a globally recognized system established by the World Health Organization (WHO) to standardize the classification of diseases and health problems. This standardization is critical for collecting and comparing health data internationally, especially mortality statistics. In the United States, the ICD is adapted into the International Classification of Diseases, Clinical Modification (ICD-CM), used for classifying morbidity in various healthcare settings. Understanding these codes is crucial for accurate medical documentation and healthcare data analysis.
ICD-CM codes play a vital role in enhancing data collection within the healthcare system. As healthcare providers increasingly focus on targeted testing and treatment for latent Tuberculosis (TB) infection, precise coding becomes essential. Distinguishing between initial latent TB infection testing and active TB disease evaluation in medical records is significantly improved with ICD-CM codes.
Recognizing this need, the Centers for Disease Control and Prevention (CDC), in collaboration with state and local TB programs and the National Center for Health Statistics (NCHS), updated and introduced new ICD-CM codes between 2017 and 2018. These revisions aim to facilitate better clinical documentation related to both latent TB infection and active TB disease. While not primarily for public health surveillance, these codes offer a valuable method to assess the adoption of healthcare recommendations and guidelines, such as screening for latent TB infection in high-risk populations. This improved data collection empowers evidence-based decision-making at both individual patient and broader population levels, and allows for monitoring trends in latent TB infection testing outside of traditional public health departments.
The 2020 ICD-10-CM update brought significant changes relevant to Tuberculosis. It’s important to note that while ICD-CM is based on WHO’s ICD, it may include modifications specific to clinical practice in the US. Among the key updates are new codes designed to specifically address latent TB infection and testing scenarios.
Key ICD-10-CM Codes for Tuberculosis Testing and Latent TB Infection:
-
Z11.7: Encounter for testing for latent tuberculosis infection. This code is particularly relevant when considering tests like the Quantiferon Gold. When a patient undergoes testing, such as a Quantiferon Gold test, to determine if they have latent TB infection, this is the appropriate diagnosis code to use. It signifies an encounter specifically for latent TB infection testing, crucial for tracking and managing potential TB cases.
-
Z86.15: Personal history of latent tuberculosis infection. This code is used to document a patient’s past diagnosis of latent TB infection. It is important for medical history and for identifying individuals who may be at higher risk for TB reactivation.
-
Z22.7: Carrier of latent tuberculosis. This code applies to individuals with a documented positive test for TB infection, but without current evidence of active TB disease. This includes those who have had a positive Quantiferon Gold test in the past, confirming latent infection but not active disease. It’s important to note that this code excludes non-specific reactions to interferon-gamma release assays (IGRAs) like Quantiferon Gold (R76.12) or tuberculin skin tests (TST) (R76.11) when active TB is not present.
Modified ICD-10-CM Code:
- Z11.1: Encounter for screening for respiratory tuberculosis. This code has been broadened to include “Encounter for screening for active tuberculosis disease.” This modification reflects the need to encompass screening for both latent and active forms of TB under this broader screening encounter category.
In conclusion, the ICD-10-CM codes, especially the newly introduced and modified codes, are essential tools for accurately documenting and tracking TB testing and latent TB infection. Using codes like Z11.7, specifically in situations where tests like Quantiferon Gold are utilized, ensures better data quality, facilitates effective monitoring of TB trends, and ultimately contributes to improved patient care and public health outcomes in the fight against Tuberculosis.
